secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001493152-26-013654
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack reports FY2025 net loss $19.4M; cash $7.4M; plans IDE filing Q2 2026
-------------------------------------------------------------------------------

- Net loss for FY2025 was $19.4M, down from $22.6M in 2024; no product revenue.
- Cash and equivalents $7.4M at Dec 31, 2025, up from $5.6M; raised $4.0M private placement in Dec 2025.
- R&D expenses $9.8M vs $9.5M; G&A $6.3M vs $5.1M year-over-year.
- Expects to file IDE with FDA in Q2 2026 to start US clinical feasibility study of implantable CBGM in H2 2026.
- Believes existing cash sufficient only through Spring 2026 to fund IDE submission and trial initiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226013654/0001493152-26-013654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226013654/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer